The report provides a detailed analysis essential for establishing a Ciproxifan production plant. It encompasses all critical aspects necessary for Ciproxifan production, including the cost of Ciproxifan production, Ciproxifan plant cost, Ciproxifan production costs, and the overall Ciproxifan production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Ciproxifan production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Ciproxifan is a compound that has been reported to antagonize a receptor in the brain known as the histamine H3 receptor. It is used to enhance attention in ADHD (attention deficit hyperactivity disorder) patients and where there is a memory issue, such as in the case of Alzheimer’s disease. It interacts with enzymes that degrade crucial brain chemicals and, therefore, is employed to boost the amounts of such chemicals in the treatment of mood disorders such as depression. It is also proposed as a possible adjuvant therapy for schizophrenia that may enhance the effectiveness of antipsychotic medications.
The market for Ciproxifan is driven by its usage as an antagonist of histamine H3 receptor used for the treatment of neurological disorders such as attention deficit hyperactivity disorder (ADHD) and Alzheimer’s disease, which significantly promotes its demand in the pharmaceutical and medical industries. The widespread occurrence of neurological disorders is significantly increasing the demand for Ciproxifan.
Additionally, Ciproxifan holds some potential for enhancing learning ability and memory and, therefore, might contribute to the development of new therapies for different forms of brain diseases, amplifying its market presence. Furthermore, the drug’s H3 receptor antagonistic activity and MAO inhibitory qualities provide opportunities for the development of dual-targeting therapeutics, which leads to more successful therapies for difficult neurological disorders, which contributes to its demand. Overall, industrial Ciproxifan procurement is influenced by its application in the pharmaceutical and medical industries, rising cases of neurological disorders, efficacy to improve cognitive functions, dual mechanism of action, and regulatory approvals.
Raw Material for Ciproxifan Production
According to the Ciproxifan production plant project report, the key raw material used in the production of Ciproxifan includes Urocanic acid.
Production Process of Ciproxifan
The extensive Ciproxifan production cost report consists of the following major industrial production process:
- Production from Urocanic acid: The production process of Ciproxifan starts the protection and function group transformation of urocanic acid to form an intermediate. An imidazole ring is introduced into the intermediate to form 3-(1H-imidazol-4-yl)propanol. The imidazolyl trityl-protected 3-(1H-imidazol-4-yl)propanol is reacted with cyclopropyl 4-hydroxyphenyl methanone (Mitsunobu reaction) with triphenylphosphine (PPh3) and diethyl azodicarboxylate (DEAD) as coupling agents in the presence of dichloromethane or toluene to form the final intermediate. Finally, the intermediate is subjected to acidic conditions to remove the trityl-protecting group to produce Ciproxifan as the final product.
Ciproxifan is a selective H3 histamine receptor antagonist having the molecular formula C16H18N2O2 and a molecular weight of 270.33 g/mol. It has an oral bioavailability of 62%. It has a Ki value in the range of 0.5 to 1.9 nM. Ciproxifan contains a cyclopropyl group, an imidazole ring, and a phenyl ketone structure, contributing to its activity as a selective H3 receptor antagonist.
